The Motley Fool Discussion Boards

Previous Page

Industry Discussions / Pharmaceuticals


Subject:  Re: Ziopharm Date:  6/4/2010  4:05 PM
Author:  Smufty2 Number:  875 of 897

More from JMP Securities:
• Management meetings enhance conviction that SPA is within grasp;reiterate Market Outperform rating and $10 price targeton Ziopharm.Werecently hosted meetings with Ziopharm management and investors,based on which we have gained incremental insights into
the final steps to securing an SPA for the palifosfamide pivotal program. With these new insights, we remain confident that the company is very close tosuccessfully completing SPA discussions with the FDA and continues to be on track to initiatethe pivotal trial in mid-2010. Additionally, with